UNCY Unicycive Therapeutics, Inc.

NASDAQ
$4.70

Unicycive Therapeutics, Inc. (UNCY) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.32 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.7% since its last earnings release on August 12, 2026.

Unicycive Therapeutics Beat Consensus Estimates
Wednesday, August 12, 2026 · 7:19 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 7:20 AM ET
Earnings Whisper
-
vs ($0.32)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.21

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company's lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc. is based in LOS ALTOS, Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.